Global Point-of-Care Testing for Women Health Market Research by Product, by Age, by Sample Type, by Test Type, by Technology, by Application, by Distribution Channel, by End User, and by Region Forecast till 2032

Description

List of Tables

Global Point-of-Care Testing for Women Health Market Research by Product (Instruments/ Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, White Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti- Mullerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-Stimulating Hormone Test, Luteinizing Hormone Test, B-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-Cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections, Fertility Conditions, Pregnancy Testing, Others), by Distribution Channel (Offline, Online), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032

Industry Overview

The Global Point-of-Care Testing for Women's Health Market is forecasted to expand to USD 28.77 billion by 2032, reflecting a steady 6.26% CAGR during 2024-2032. POCT for women's health is a multipurpose, easy-to-access diagnostic tool giving immediate and on-the-go results of critical conditions, such as reproductive health, infectious diseases, and pregnancy-related complications. Originally intended for the disabled, these tests are also accessible at hospitals, clinics, or simply at home. Their rapidity, and at the same time, good affordability and reliability allow them to become keys in the whole preventive care and early medical intervention process serious cases.

Growing cases of sexually transmitted infections, urinary tract infections, and HPV among women highlight the urgent need for rapid detection tools. POC testing addresses this gap with quick and reliable results, supporting early diagnosis and intervention. The rising infection burden is propelling adoption, as women's health outcomes depend on timely treatment and accessible testing solutions.

Key Company Development

Swiss Precision Diagnostics GmbH has demonstrated consistent innovation in advancing diagnostic solutions for women's health. In August 2023, the company launched the Clearblue Menopause Stage Indicator, a first-of-its-kind home-use product that evaluates menopause stages by integrating urinary FSH measurements with age and cycle data. This innovation empowers women with greater understanding of reproductive transitions, fostering informed health decisions. Complementing this milestone, SPD in August 2020 implemented the Matrix Gemini LIMS to optimize data management in pregnancy studies. This technology enhanced accessibility, streamlined laboratory workflows, and improved biobank operations, reflecting the company's strong emphasis on digital transformation. These strategic moves reinforce SPD's leadership in combining product innovation and advanced technologies to deliver precision-driven women's health diagnostics.

Key Players

Major players in the global point-of-care testing for women health market are Swiss Precision Diagnostics GmbH (SPD), Wondfo, Church & Dwight Co., Inc., Hangzhou Singclean, Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, Innovita Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., and Chungdo Pharm Co., Ltd.

Report Attribute Details

Market Size 2023 USD 16,627.22 Million

Market Size 2032 USD 28,768.16 Million

CAGR (2024-2032) 6.26%

Base Year 2023

Market Forecast Period 2024-2032

Historical Data 2019-2024

Industry Segmentations CAGR (2024-2032)

By Product: Instruments/ Devices - 7.72%, Reagents & Kits - 5.97%.

By Age: Adolescent - 8.18%, Adult - 6.20%.

By Sample Type: Serum - 5.27%, Plasma - 4.30%.

By Test Type: Testosterone Test - 4.12%, Estradiol Test - 3.53%.

By Technology: Colloidal Gold Lateral Flow Assays - 7.19%, Fluorescence Immunoassays - 5.46%.

By Application: Gestational Diabetes - 5.34%, Vaginal Infection - 4.08%.

By Distribution Channel: Offline - 5.49%, Online - 7.35%.

By End User: Hospitals - 5.42 %, Diagnostic Laboratories - 6.96%.

Regional Analysis

The women's health POCT market in North America rides on the back of consumer demand for quick and reliable testing. High awareness in conjunction with well-organized healthcare systems acts as a springboard for wide use in hospital as well as home-care environments. In 2023, North America's market was led by the US, followed by Canada and Mexico, with respective market values of USD 5,735.44 million, USD 889.72 million, and USD 426.32 million.

Innovation is thriving in the European market, and there is an increasing emphasis on personalized medicine. The use of cutting-edge diagnostic platforms is growing, with the primary objective being early detection of diseases that range from reproductive health to chronic conditions. In 2023, Germany, the UK, and France were the top three European markets, contributing USD 1,220.06 million, USD 906.19 million, and USD 775.11 million.

Asia-Pacific demonstrates remarkable growth potential, propelled by expanding healthcare access in China, India, and Southeast Asia. In 2023, the APAC region China, India, and Japan, is the leading market, with market sizes of USD 751.65 million, USD 634.81 million, and USD 607.31 million. A rising incidence of pregnancy-related complications and chronic illnesses is driving reliance on POCT solutions.

Markets in the Middle East, Africa, and South America are witnessing steady adoption of POCT, largely due to limited access to traditional laboratory infrastructure. Portable diagnostic technologies are emerging as vital tools in addressing reproductive health challenges.

Product Code: MRFR/HC/58150-CR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES IN WOMEN
- 4.2.2 INCREASING CASES OF INFERTILITY AMONG WOMEN
- 4.2.3 GROWING STRATEGIC INITIATIVES ASSOCIATED WITH THE POINT-OF-CARE TESTING FOR WOMEN HEALTH
4.3 RESTRAINTS
- 4.3.1 INACCURACY OF POINT OF CARE DIAGNOSTIC TESTS
4.4 OPPORTUNITY
- 4.4.1 RISING AWARENESS AND HEALTH INITIATIVES
- 4.4.2 HIGH COST OF DIAGNOSTIC IMAGING SYSTEMS AND PROCEDURES

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET
5.3 CONSUMER PREFERENCE ANALYSIS
5.4 REGULATORY LANDSCAPE AND ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS
- 5.4.1 REGULATORY LANDSCAPE
- 5.4.2 ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS
5.5 EFFECTS OF TRANSITION OF IVDD TO IVDR ON GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET

6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 INSTRUMENTS/DEVICES
6.3 REAGENTS & KITS
6.4 CONSUMABLES

7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE

7.1 OVERVIEW
7.2 ADOLESCENT
7.3 ADULT
7.4 GERIATRIC

8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE

8.1 OVERVIEW
8.2 SERUM
8.3 PLASMA
8.4 WHOLE BLOOD
8.5 URINE
8.6 OTHERS

9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE

9.1 OVERVIEW
9.2 TESTOSTERONE TEST
9.3 ESTRADIOL TEST
9.4 ANTI-MULLERIAN HORMONE TEST
9.5 PROLACTIN TEST
9.6 PROGESTERONE TEST
9.7 FOLLICLE-STIMULATING HORMONE TEST
9.8 LUTEINIZING HORMONE TEST
9.9 B-HCG TEST
9.10 OTHERS

10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY

10.1 OVERVIEW
10.2 COLLOIDAL GOLD LATERAL FLOW ASSAYS
10.3 FLUORESCENCE IMMUNOASSAYS
10.4 LAB-ON-A-CHIP
10.5 OTHERS

11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION

11.1 OVERVIEW
11.2 GESTATIONAL DIABETES
11.3 VAGINAL INFECTION
11.4 URINARY TRACT INFECTION
11.5 CERVICAL CANCER OR PRE-CANCEROUS CONDITIONS
11.6 HEMOGLOBIN DEFICIENCY
11.7 BREAST CANCER
11.8 THYROID DISEASE
11.9 SEXUALLY TRANSMITTED INFECTIONS
- 11.9.1 CHLAMYDIA
- 11.9.2 GONORRHEA
- 11.9.3 HIV
- 11.9.4 SYPHILIS
- 11.9.5 OTHERS
11.10 FERTILITY CONDITIONS
- 11.10.1 POLYCYSTIC OVARY SYNDROME
- 11.10.2 OVULATION DISORDERS
- 11.10.3 OTHERS
11.11 PREGNANCY TESTING
11.12 OTHERS

12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW
12.2 OFFLINE
- 12.2.1 HOSPITAL PHARMACIES
- 12.2.2 RETAIL PHARMACIES
- 12.2.3 HYPERMARKET/SUPERMARKET
12.3 ONLINE
- 12.3.1 E-COMMERCE PLATFORMS
- 12.3.2 ONLINE PHARMACIES

13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER

13.1 OVERVIEW
13.2 HOSPITALS
13.3 DIAGNOSTIC LABORATORIES
13.4 HOME SETTINGS
13.5 OTHERS

14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION

14.1 OVERVIEW
14.2 NORTH AMERICA
- 14.2.1 US
- 14.2.2 CANADA
- 14.2.3 MEXICO
14.3 EUROPE
- 14.3.1 GERMANY
- 14.3.2 FRANCE
- 14.3.3 UK
- 14.3.4 ITALY
- 14.3.5 SPAIN
- 14.3.6 REST OF EUROPE
14.4 ASIA-PACIFIC
- 14.4.1 CHINA
- 14.4.2 INDIA
- 14.4.3 JAPAN
- 14.4.4 AUSTRALIA
- 14.4.5 SOUTH KOREA
- 14.4.6 SOUTH EAST ASIA
  - 14.4.6.1 MALAYSIA
  - 14.4.6.2 SINGAPORE
  - 14.4.6.3 THAILAND
  - 14.4.6.4 VIETNAM
  - 14.4.6.5 PHILIPPINES
  - 14.4.6.6 INDONESIA
  - 14.4.6.7 REST OF SOUTH EAST ASIA
- 14.4.7 REST OF ASIA-PACIFIC
14.5 REST OF THE WORLD
- 14.5.1 MIDDLE EAST & AFRICA
- 14.5.2 SOUTH AMERICA
  - 14.5.2.1 BRAZIL
  - 14.5.2.2 ARGENTINA
  - 14.5.2.3 CHILE
  - 14.5.2.4 REST OF SOUTH AMERICA

15 COMPETITIVE LANDSCAPE

15.1 INTRODUCTION
15.2 MARKET SHARE ANALYSIS, 2023
15.3 COMPETITOR DASHBOARD
15.4 PUBLIC PLAYERS STOCK SUMMARY
15.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
15.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 15.6.1 PRODUCT LAUNCH
- 15.6.2 TECHNOLOGY LAUNCH
- 15.6.3 AQUISITION
- 15.6.4 PRODUCT RECOGNITION

16 COMPANY PROFILES

16.1 SWISS PRECISION DIAGNOSTICS GMBH - CLEARBLUE
- 16.1.1 COMPANY OVERVIEW
- 16.1.2 PRODUCTION OVERVIEW
- 16.1.3 FINANCIAL OVERVIEW
- 16.1.4 PRODUCTS OFFERED
- 16.1.5 DISTRIBUTION CHANNEL
- 16.1.6 PRICE ANALYSIS
- 16.1.7 PROMOTION STRATEGY
- 16.1.8 TECHNOLOGY ANALYSIS
- 16.1.9 KEY DEVELOPMENTS
- 16.1.10 SWOT ANALYSIS
- 16.1.11 KEY STRATEGIES
16.2 WONDFO
- 16.2.1 COMPANY OVERVIEW
- 16.2.2 PRODUCTION OVERVIEW
- 16.2.3 FINANCIAL OVERVIEW
- 16.2.4 PRODUCTS OFFERED
- 16.2.5 TECHNOLOGY
- 16.2.6 KEY DEVELOPMENTS
- 16.2.7 SWOT ANALYSIS
- 16.2.8 KEY STRATEGIES
16.3 CHURCH & DWIGHT CO., INC. - FIRST RESPONSE
- 16.3.1 COMPANY OVERVIEW
- 16.3.2 PRODUCTION OVERVIEW
- 16.3.3 FINANCIAL OVERVIEW
- 16.3.4 PRODUCTS OFFERED
- 16.3.5 DISTRIBUTION CHANNEL
- 16.3.6 PRICE ANALYSIS
- 16.3.7 PROMOTION
- 16.3.8 TECHNOLOGY ANALYSIS
- 16.3.9 KEY DEVELOPMENTS
- 16.3.10 SWOT ANALYSIS
- 16.3.11 KEY STRATEGIES
16.4 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.
- 16.4.1 COMPANY OVERVIEW
- 16.4.2 PRODUCTION OVERVIEW
- 16.4.3 FINANCIAL OVERVIEW
- 16.4.4 PRODUCT OFFERED
- 16.4.5 TECHNOLOGY ANALYSIS
- 16.4.6 KEY DEVELOPMENTS
- 16.4.7 KEY STRATEGIES
16.5 W.H.P.M., INC.
- 16.5.1 COMPANY OVERVIEW
- 16.5.2 PRODCUTION OVERVIEW
- 16.5.3 FINANCIAL OVERVIEW
- 16.5.4 PRODUCTS OFFERED
- 16.5.5 TECHNOLOGY ANALYSIS
- 16.5.6 KEY DEVELOPMENTS
- 16.5.7 KEY STRATEGIES
16.6 SEKISUI DIAGNOSTICS
- 16.6.1 COMPANY OVERVIEW
- 16.6.2 PRODUCTION OVERVIEW
- 16.6.3 FINANCIAL OVERVIEW
- 16.6.4 PRODUCTS OFFERED
- 16.6.5 TECHNOLOGY ANALYSIS
- 16.6.6 KEY DEVELOPMENTS
- 16.6.7 SWOT ANALYSIS
- 16.6.8 KEY STRATEGIES
16.7 INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD
- 16.7.1 COMPANY OVERVIEW
- 16.7.2 FINANCIAL OVERVIEW
- 16.7.3 PRODUCTS OFFERED
- 16.7.4 TECHNOLOGY ANALYSIS
- 16.7.5 KEY DEVELOPMENTS
- 16.7.6 KEY STRATEGIES
16.8 YANGZHOU VIOMED
- 16.8.1 COMPANY OVERVIEW
- 16.8.2 PRODUCTION OVERVIEW
- 16.8.3 FINANCIAL OVERVIEW
- 16.8.4 PRODUCTS OFFERED
- 16.8.5 TECHNOLOGY ANALYSIS
- 16.8.6 KEY DEVELOPMENTS
- 16.8.7 KEY STRATEGIES
16.9 COFOE MEDICAL TECHNOLOGY CO., LTD.
- 16.9.1 COMPANY OVERVIEW
- 16.9.2 PRODUCTION OVERVIEW
- 16.9.3 FINANCIAL OVERVIEW
- 16.9.4 PRODUCTS OFFERED
- 16.9.5 KEY DEVELOPMENTS
- 16.9.6 TECHNOLOGY ANALYSIS
- 16.9.7 SWOT ANALYSIS
- 16.9.8 KEY STRATEGIES
16.10 CHUNGDO PHARM CO., LTD.
- 16.10.1 COMPANY OVERVIEW
- 16.10.2 PRODUCTION OVERVIEW
- 16.10.3 FINANCIAL OVERVIEW
- 16.10.4 PROUDCTS OFFERED
- 16.10.5 TECHNOLOGY ANALYSIS
- 16.10.6 KEY DEVELOPMENTS
- 16.10.7 KEY STRATEGIES
16.11 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.
- 16.11.1 COMPANY OVERVIEW
- 16.11.2 PRODUCTION OVERVIEW
- 16.11.3 FINANCIAL OVERVIEW
- 16.11.4 PRODUCTS OFFERED
- 16.11.5 TECHNOLOGY ANALYSIS
- 16.11.6 KEY DEVELOPMENTS
- 16.11.7 SWOT ANALYSIS
- 16.11.8 KEY STRATEGIES
16.12 EASY HEALTHCARE CORPORATION
- 16.12.1 COMPANY OVERVIEW
- 16.12.2 PRODUCTION OVERVIEW
- 16.12.3 FINANCIAL OVERVIEW
- 16.12.4 PRODUCTS OFFERED
- 16.12.5 TECHNOLOGY
- 16.12.6 KEY DEVELOPMENTS
- 16.12.7 KEY STRATEGIES

17 DATA CITATIONS